Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
نویسندگان
چکیده
منابع مشابه
Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
The objectives of this study were to assess the safety and efficacy of darbepoetin alfa (Aranesp) administered every 2 weeks in anemic patients with solid tumors receiving chemotherapy. This was an open-label, randomized, active-controlled, multicenter dose-finding study evaluating a range of every-2-week darbepoetin alfa doses. The active control arm received epoetin alfa (Epogen, Procrit) at ...
متن کاملDarbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-w...
متن کاملEffects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
PURPOSE/OBJECTIVES To review the effects on hemoglobin and quality of life of an every-two-week (Q2W) regimen of the erythropoietic agent darbepoetin alfa for treating patients with chemotherapy-induced anemia. DATA SOURCES Published articles and abstracts. DATA SYNTHESIS Darbepoetin alfa Q2W increases hemoglobin in patients with chemotherapy-associated anemia and is well tolerated. Increas...
متن کاملDose–Conversion Ratio for Epoetin Alfa and Darbepoetin Alfa in Chemotherapy Patients with Anemia and Cancer
INTRODUCTION Anemia is a common complication of myelosuppressive chemotherapies in patients with cancer.1 When untreated, chemotherapy-induced anemia (CIA) may adversely affect the patient’s quality of life and ability to function because of symptoms such as fatigue, weakness, shortness of breath, and impaired mental function.2-4 Red blood cell (RBC) transfusions can be used to correct anemia, ...
متن کاملEvery-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoetin alfa clinical studies. All studies enrolled anemic (hemoglobin < or = 11.0 g/dL) patients receiving multicycle chemotherapy. Open-label study d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 2002
ISSN: 0007-0920,1532-1827
DOI: 10.1038/sj.bjc.6600465